CDT Equity (NASDAQ:CDT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of CDT Equity (NASDAQ:CDT) from a sell rating to a hold rating in a research note issued to investors on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CDT Equity in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, CDT Equity currently has a consensus rating of “Sell”.

CDT Equity Stock Performance

NASDAQ:CDT opened at $1.68 on Friday. CDT Equity has a fifty-two week low of $1.60 and a fifty-two week high of $2,739.80. The company has a 50 day simple moving average of $3.79 and a two-hundred day simple moving average of $50.57. The company has a market capitalization of $1.33 million, a PE ratio of -0.00 and a beta of 1.52.

CDT Equity (NASDAQ:CDT) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($8.71) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On CDT Equity

An institutional investor recently bought a new stake in CDT Equity stock. Great Lakes Advisors LLC bought a new position in shares of CDT Equity Inc. (NASDAQ:CDT) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 18,631 shares of the company’s stock, valued at approximately $991,000. Great Lakes Advisors LLC owned 2.96% of CDT Equity at the end of the most recent reporting period. Hedge funds and other institutional investors own 3.29% of the company’s stock.

About CDT Equity

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.